Arrowstreet Capital, Limited Partnership Bristol Myers Squibb CO Transaction History

Arrowstreet Capital, Limited Partnership

$121 Billion
Q3 2024

A detailed history of Arrowstreet Capital, Limited Partnership transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Arrowstreet Capital, Limited Partnership holds 2,031,175 shares of BMY stock, worth $117 Million. This represents 0.09% of its overall portfolio holdings.

Number of Shares

2,031,175

Previous 2,919,501 30.43%

Holding current value

$117 Million

Previous $121 Million 13.31%

% of portfolio

0.09%

Previous 0.11%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$39.66 - $51.75 $35.2 Million - $46 Million	-888,326 Reduced 30.43%	2,031,175 $105 Million
Q2 2024 Aug 14, 2024	SELL	$40.25 - $52.99 $16.6 Million - $21.8 Million	-412,074 Reduced 12.37%	2,919,501 $121 Million
Q1 2024 May 15, 2024	BUY	$47.98 - $54.4 $136 Million - $155 Million	2,840,308 Added 578.16%	3,331,575 $181 Million
Q4 2023 Feb 14, 2024	BUY	$48.48 - $57.85 $15.5 Million - $18.5 Million	319,553 Added 186.1%	491,267 $25.2 Million
Q3 2023 Nov 14, 2023	BUY	$57.89 - $64.73 $9.94 Million - $11.1 Million	171,714 New	171,714 $9.97 Million
Q1 2023 May 15, 2023	BUY	$65.71 - $74.53 $47.4 Million - $53.8 Million	721,425 Added 272.77%	985,908 $68.3 Million
Q4 2022 Feb 14, 2023	SELL	$68.48 - $81.09 $678,773 - $803,764	-9,912 Reduced 3.61%	264,483 $19 Million
Q3 2022 Nov 14, 2022	BUY	$0.13 - $76.84 $35,671 - $21.1 Million	274,395 New	274,395 $19.5 Million
Q2 2022 Aug 15, 2022	SELL	$72.62 - $79.98 $158 Million - $174 Million	-2,181,468 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$61.48 - $73.72 $245 Million - $294 Million	-3,985,365 Reduced 64.63%	2,181,468 $159 Million
Q4 2021 Feb 14, 2022	BUY	$53.63 - $62.52 $7.09 Million - $8.27 Million	132,211 Added 2.19%	6,166,833 $385 Million
Q3 2021 Nov 12, 2021	BUY	$59.17 - $69.31 $282 Million - $331 Million	4,769,885 Added 377.14%	6,034,622 $357 Million
Q2 2021 Aug 13, 2021	BUY	$61.91 - $67.42 $78.3 Million - $85.3 Million	1,264,737 New	1,264,737 $84.5 Million
Q3 2020 Nov 12, 2020	SELL	$57.43 - $63.64 $62.7 Million - $69.5 Million	-1,092,148 Closed	0 $0
Q2 2020 Aug 12, 2020	SELL	$54.82 - $64.09 $61.1 Million - $71.4 Million	-1,113,891 Reduced 50.49%	1,092,148 $64.2 Million
Q1 2020 May 15, 2020	BUY	$46.4 - $67.43 $102 Million - $149 Million	2,206,039 New	2,206,039 $123 Million
Q4 2019 Feb 13, 2020	SELL	$49.21 - $64.19 $138 Million - $180 Million	-2,804,704 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$42.77 - $50.71 $283 Million - $335 Million	-6,614,511 Reduced 70.22%	2,804,704 $142 Million
Q2 2019 Aug 14, 2019	SELL	$44.62 - $49.34 $237 Million - $262 Million	-5,319,461 Reduced 36.09%	9,419,215 $427 Million
Q1 2019 May 15, 2019	SELL	$45.12 - $53.8 $1.18 Million - $1.41 Million	-26,183 Reduced 0.18%	14,738,676 $703 Million
Q4 2018 Feb 14, 2019	BUY	$48.76 - $63.23 $14.6 Million - $18.9 Million	299,601 Added 2.07%	14,764,859 $767 Million
Q3 2018 Nov 14, 2018	BUY	$55.19 - $62.25 $29.4 Million - $33.1 Million	532,413 Added 3.82%	14,465,258 $898 Million
Q2 2018 Aug 14, 2018	BUY	$50.53 - $62.98 $372 Million - $464 Million	7,362,915 Added 112.07%	13,932,845 $771 Million
Q1 2018 May 14, 2018	BUY	$59.92 - $68.98 $4.54 Million - $5.22 Million	75,710 Added 1.17%	6,569,930 $416 Million
Q4 2017 Feb 09, 2018	BUY	$59.94 - $65.35 $85 Million - $92.6 Million	1,417,638 Added 27.93%	6,494,220 $398 Million
Q3 2017 Nov 14, 2017	BUY	$55.23 - $63.74 $280 Million - $324 Million	5,076,582	5,076,582 $324 Million

Others Institutions Holding BMY

# of Institutions

2,536

Shares Held

1.47B

Call Options Held

31.6M

Put Options Held

35M

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $123B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Arrowstreet Capital, Limited Partnership, based on Form 13F filings with the SEC.

News

Stay updated on Arrowstreet Capital, Limited Partnership with notifications on news.

Account

Arrowstreet Capital, Limited Partnership Bristol Myers Squibb CO Transaction History